CAG
MYGN icon

Crestwood Advisors Group’s Myriad Genetics MYGN Stock Holding History

Crestwood Advisors Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-22,943
Closed -$780K – 154
2015
Q2 		$780K Sell
22,943
-256,091
-92% -$8.71M 0.1% 70
2015
Q1 		$9.88M Buy
279,034
+29,921
+12% +$1.07M 1.41% 40
2014
Q4 		$8.48M Buy
249,113
+14,213
+6% +$504K 1.28% 41
2014
Q3 		$9.06M Sell
234,900
-56,544
-19% -$2.11M 1.42% 33
2014
Q2 		$11.3M Buy
291,444
+4,719
+2% +$176K 1.81% 22
2014
Q1 		$9.8M Buy
+286,725
New +$8.88M 1.6% 27

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crestwood Advisors Group's MYGN Position: Q3 2015 in Review

Crestwood Advisors Group sold out of Myriad Genetics (MYGN) in Q3 2015, closing a stake of 22,943 shares — an estimated $780K sold.

Crestwood Advisors Group first reported a position in MYGN in Q1 2014 and held it in 6 quarters. The position peaked at $11.3M in Q2 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q3 2015.

  • Crestwood Advisors Group reported no remaining Myriad Genetics position as of Q3 2015 after selling out during the quarter.
  • Crestwood Advisors Group sold 22,943 Myriad Genetics shares in Q3 2015, an estimated $780K.
  • Crestwood Advisors Group first reported a position in Myriad Genetics in Q1 2014 and held it in 6 quarters.
  • Crestwood Advisors Group's Myriad Genetics position peaked at $11.3M in Q2 2014.
  • 234 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2015.

Based on Crestwood Advisors Group's 13F filing for Q3 2015, filed 16 Nov 2015.